Greater adherence to a Mediterranean diet is associated with a significant improvement in health status, as seen by a significant reduction in overall mortality (9%), mortality from cardiovascular diseases (9%), incidence of or mortality from cancer (6%), and incidence of Parkinson's disease and Alzheimer's disease (13%). 3 key findings →
Design: meta-analysis
Participants: 574,299
Evidence: high
Full summary, score breakdown and related studies →
Original source
Rare variants in the coding sequence of triggering receptor expressed on myeloid cells 2 (TREM2) have been identified in Alzheimer's disease (AD). 5 key findings →
Design: meta-analysis
Participants: 26
Evidence: high
Full summary, score breakdown and related studies →
Original source
83/100
✓ Peer-reviewed
alzhub usefulness score 83 out of 100.
·
BMC medicine
·
2014-03-22
Our systematic review and meta-analyses indicate that high quality observational data can provide relevant evidence on unintended effects of statins to add to the evidence from RCTs. 5 key findings →
Design: systematic review
Participants: 1,000
Evidence: high
Full summary, score breakdown and related studies →
Original source
ARIA remains a significant safety concern in anti-amyloid mAb therapy, with incidence and severity influenced by genetic, neuroimaging, and treatment-related factors. 4 key findings →
Design: systematic review
Participants: 20
Evidence: high
Full summary, score breakdown and related studies →
Original source
82/100
✓ Peer-reviewed
alzhub usefulness score 82 out of 100.
·
Nature Medicine
·
2025-04-21
Dementia is a leading cause of death and disability worldwide. 3 key findings →
Design: RCT
Participants: 33,995
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
82/100
✓ Peer-reviewed
alzhub usefulness score 82 out of 100.
·
JAMA
·
2008-11-01
In this study, G. biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly individuals with normal cognition or those with MCI. 4 key findings →
Participants: 2,587
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
82/100
✓ Peer-reviewed
alzhub usefulness score 82 out of 100.
·
Neurology
·
2020-07-01
The incidence rate of dementia in Europe and North America has declined by 13% per decade over the past 25 years, consistently across studies. 2 key findings →
Design: cohort study
Participants: 49,202
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The crude incidence rate was 16 (CI: 13-20) cases per 1,000 person-years (pyr) with 17 (CI: 12-21) per 1,000 pyr for females and 14 (CI: 9-21) per 1,000 pyr for males. 5 key findings →
Design: meta-analysis
Participants: 748
Evidence: high
Full summary, score breakdown and related studies →
Original source
Pooling data on more than 600,000 people, this meta-analysis found that people who reported feeling lonely had about a 30% higher risk of developing dementia overall, and even higher risk for vascular dementia specifically, even after accounting for depression and objective social isolation. 4 key findings →
Design: meta-analysis
Participants: 608,561
Evidence: high
Full summary, score breakdown and related studies →
Original source
81/100
✓ Peer-reviewed
alzhub usefulness score 81 out of 100.
·
JAMA Psychiatry
·
2023-06-01
Further studies are warranted to develop and refine the specific MIND diet for different populations. 4 key findings →
Design: meta-analysis
Participants: 224,049
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The 172 total participants had a mean (SD) age of 75.7 (4.8) years, and 108 (62.8%) were women. 4 key findings →
Participants: 172
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
After a median of 4.7 years of follow-up, the rate of cardiovascular disease was 10.7 events per 1000 person-years in the aspirin group and 11.3 events per 1000 person-years in the placebo group (hazard ratio, 0.95; 95% confidence interval [CI], 0.83 to 1.08). 4 key findings →
Participants: 19,114
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
81/100
✓ Peer-reviewed
alzhub usefulness score 81 out of 100.
·
Gastroenterology
·
2019-05-29
In a large placebo-controlled randomized trial, we found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections. 5 key findings →
Design: randomized controlled trial
Participants: 8,791
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
In analyses that addressed bias due to reverse causation, physical inactivity was not associated with all-cause dementia or Alzheimer's disease, although an indication of excess dementia risk was observed in a subgroup of physically inactive individuals who developed cardiometabolic disease. 2 key findings →
Design: meta-analysis
Participants: 404
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Prevention of cognitive impairment and dementia is an important public health goal. 4 key findings →
Design: systematic review
Participants: 11,140
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
81/100
✓ Peer-reviewed
alzhub usefulness score 81 out of 100.
·
Age and ageing
·
2014-03-06
We aimed to synthesise data on risk factors for incident delirium and where possible conduct meta-analysis of these. 4 key findings →
Design: systematic review
Participants: 411
Evidence: high
Full summary, score breakdown and related studies →
Original source
81/100
✓ Peer-reviewed
alzhub usefulness score 81 out of 100.
·
Heart rhythm
·
2012-08-02
AF is independently associated with increased risk of dementia. 5 key findings →
Design: meta-analysis
Participants: 77,668
Evidence: high
Full summary, score breakdown and related studies →
Original source
81/100
✓ Peer-reviewed
alzhub usefulness score 81 out of 100.
·
BMJ open
·
2021-06-09
Profiles of high risk for future dementia are well understood and are likely to concern mostly those in low-income and middle-income countries and people at greater disadvantage in high-income countries. 1 key finding →
Design: randomized controlled trial
Participants: 2,400
Evidence: high
Full summary, score breakdown and related studies →
Original source
Our findings show that the first months of the outbreak did not significantly impact the cognition, quality of life, perceived health status, and depression of our study population when making comparisons with baseline assessments prior to the outbreak. 5 key findings →
Design: cohort study
Participants: 75
Evidence: high
Full summary, score breakdown and related studies →
Original source
Due to the small number of studies and heterogeneity in study design and outcomes, the association between DNA methylation age and age-related disease and longevity is inconclusive. 3 key findings →
Design: systematic review
Participants: 41,607
Evidence: high
Full summary, score breakdown and related studies →
Original source
Regarding exposures to air pollution, there was convincing (class I) evidence for the association between long-term exposure to solvents and a higher incidence of dementia or cognitive impairment (odds ratio, OR=1.139), and highly suggestive (class II) evidence for the association between long-term exposure to some pollutants and higher risk for cognitive disorders (higher incidence of dementia with high vs. low levels of carbon monoxide, CO: OR=1.587; higher incidence of vascular dementia per 1 μg/m 3 increase of nitrogen oxides, NO x : hazard ratio, HR=1.004). 1 key finding →
Design: systematic review
Participants: 195
Evidence: high
Full summary, score breakdown and related studies →
Original source
More than 25% of the U.S. population aged ≥ 65 years has diabetes mellitus (hereafter referred to as diabetes),1 and the aging of the overall population is a significant driver of the diabetes epidemic. 5 key findings →
Design: meta-analysis
Participants: 1,000
Evidence: high
Full summary, score breakdown and related studies →
Original source
The first single-stage individual patient data meta-analysis from randomized double-blind placebo-controlled clinical trials provides evidence to support benefits of antihypertensive treatment in late-mid and later life to lower the risk of dementia. 5 key findings →
Design: meta-analysis
Participants: 28,008
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
We identified 22 hospital-based and eight population-based eligible cohorts (7511 patients) described in 73 papers. 2 key findings →
Design: systematic review
Participants: 7,511
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
80/100
✓ Peer-reviewed
alzhub usefulness score 80 out of 100.
·
JAMA
·
2004-06-01
In the estrogen-alone trial, 47 participants were diagnosed with probable dementia, of whom 28 were assigned to CEE and 19 to placebo (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.83-2.66). 3 key findings →
Participants: 4,532
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 31,380 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.